An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.

Autor: Reyes Gaido OE; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Pavlaki N; Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA., Granger JM; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Mesubi OO; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Liu B; Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA., Lin BL; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Long A; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Walker D; Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA., Mayourian J; Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA., Schole KL; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Terrillion CE; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Nkashama LJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Hulsurkar MM; Cardiovascular Research Institute and Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA., Dorn LE; Cardiovascular Research Institute and Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA., Ferrero KM; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Huganir RL; Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA., Müller FU; Institute of Pharmacology and Toxicology, University of Münster, Münster 48149, Germany., Wehrens XHT; Cardiovascular Research Institute and Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.; Departments of Medicine, Neuroscience, and Pediatrics, Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Liu JO; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Luczak ED; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Bezzerides VJ; Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA., Anderson ME; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Division of Biological Sciences and the Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2023 Jun 21; Vol. 15 (701), pp. eabq7839. Date of Electronic Publication: 2023 Jun 21.

GRK2 in cardiovascular disease and its potential as a therapeutic target.

Autor: Ferrero KM; Lewis Katz School of Medicine at Temple University, Department of Cardiovascular Sciences, Philadelphia, PA, USA; Lewis Katz School of Medicine at Temple University, Center for Translational Medicine, Philadelphia, PA, USA., Koch WJ; Lewis Katz School of Medicine at Temple University, Department of Cardiovascular Sciences, Philadelphia, PA, USA; Lewis Katz School of Medicine at Temple University, Center for Translational Medicine, Philadelphia, PA, USA. Electronic address: walter.koch@temple.edu.

Publikováno v: Journal of molecular and cellular cardiology [J Mol Cell Cardiol] 2022 Nov; Vol. 172, pp. 14-23. Date of Electronic Publication: 2022 Jul 22.